Von Willebrand Factor and Intima-Media Thickness in Patients With Rheumatoid Arthritis: A Cross-Sectional Study
Full Text


Rheumatoid Arthritis
von Willebrand Factor
Cardiovascular Risk

How to Cite

Fedorovych, K., & Yatsyshyn, R. (2023). Von Willebrand Factor and Intima-Media Thickness in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Galician Medical Journal, 30(1), E202311. https://doi.org/10.21802/gmj.2023.1.1


Background. Cardiovascular risk assessment in patients with rheumatoid arthritis (RA) is often a real challenge and requires the search for new indicators to reveal the potential threat of developing atherosclerotic vascular lesions in the early stages.

The study aimed to analyse the association between von Willebrand factor (vWF), disease activity, and intima-media thickness (IMT) score in RA patients.

Materials and Methods. The study involved 60 RA patients divided into three groups based on the Disease Activity Score 28 (DAS-28) activity index and 20 individuals as healthy controls. Clinical and laboratory assessments included determining the number of swollen (SJ) and painful joints (PJ), the visual analogue scale (VAS) score, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fibrinogen. The concentration of vWF in blood plasma was determined by an enzyme-linked immunosorbent assay (ELISA). The IMT was measured at the bifurcation of the external and internal carotid arteries. Asymptomatic vascular damage was identified as the IMT > 0.9 mm; an atherosclerotic plaque was verified when a focal structure encroached ≥ 0.5 mm or 50% of the adjacent IMT value into the carotid lumen or the IMT > 1.5 mm.

Results. Most RA patients (39/60; 65.0%) showed an increase in the IMT (> 0.9 mm); atherosclerotic plaques (IMT > 1.5 mm) were confirmed in 16 (26.7%) individuals, which was significantly more as compared to the control group. VWF was positively associated with the IMT [OR 1.1 (1.06-1.2), p < 0.001]. In addition, elevated levels of vWF were associated with disease activity. The highest values of vWF were found in patients with moderate RA activity (43.3 [21.2-56.9]). There was a positive correlation between vWF and ESR, CRP, DAS-28 (0.564, 0.455, and 0.573, respectively).

Conclusions. There was a positive correlation between vWF, inflammatory markers, and disease activity. VWF appeared to be a reliable predictor of the IMT score in RA patients.

Full Text


Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501–507. Available from: https://doi.org/10.1159/000493390

Chodara AM, Wattiaux A, Bartels CM. Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches. Current Rheumatology Reports. 2017;19(4):16. Available from: https://doi.org/10.1007/s11926-017-0643-y

Mal K, Kumar R, Mansoor F, Kaur N, Kumar A, Memon S, et al. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis. cureus. 2020;12(12):e12246. Available from: https://doi.org/10.7759/cureus.12246

Hossain MdB, Kopec JA, Atiquzzaman M, Karim ME. The association between rheumatoid arthritis and cardiovascular disease among adults in the United States during 1999–2018, and age-related effect modification in relative and absolute scales. Annals of Epidemiology. 2022;71:23–30. Available from: https://doi.org/10.1016/j.annepidem.2022.03.005

Weber B, Weisenfeld D, Seyok T, Huang S, Massarotti E, Barrett L, et al. Relationship Between risk of atherosclerotic cardiovascular disease, inflammation, and coronary microvascular dysfunction in rheumatoid arthritis. Journal of the American Heart Association. 2022;11:e025467. Available from: https://doi.org/10.1161/JAHA.121.025467

Zhang M, Wang M, Tai Y, Tao J, Zhou W, Han Y, et al. Triggers of cardiovascular diseases in rheumatoid arthritis. Current Problems in Cardiology. 2022;47(6):100853. Available from: https://doi.org/10.1016/j.cpcardiol.2021.100853

Vicente GNS, Pereira IA, de Castro GRW, da Mota LMH, Carnieletto AP, de Souza DGS, et al. Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study. Advances in Rheumatology. 2021;61(1):38. Available from: https://doi.org/10.1186/s42358-021-00186-4

Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, et al. The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. International Journal of Molecular Sciences. 2020;21(24):9505. Available from: https://doi.org/10.3390/ijms21249505

Venetsanopoulou AI, Pelechas E, Voulgari PV, Drosos AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatology International. 2020;40(8):1181–1191. Available from: https://doi.org/10.1007/s00296-020-04616-2

Ferraz-Amaro I, Corrales A, Atienza-Mateo B, Vegas-Revenga N, Prieto-Peña D, Sánchez-Martín J, et al. SCORE2 assessment in the calculation of cardiovascular risk in patients with rheumatoid arthritis. Diagnostics. 2021;11(12):2363. Available from: https://doi.org/10.3390/diagnostics11122363

Zeineddin A, Dong J-F, Wu F, Terse P, Kozar RA. Role of von Willebrand Factor after injury: it may do more than we think. Shock. 2020;55(6):717–722. Available from: https://doi.org/10.1097/SHK.0000000000001690

Villmann J-M, Burkhardt R, Teren A, Villmann T, Thiery J, Drogies T. Atherosclerosis, myocardial infarction and primary hemostasis: impact of platelets, von Willebrand factor and soluble glycoprotein VI. Thrombosis Research. 2019;180:98–104. Available from: https://doi.org/10.1016/j.thromres.2019.06.014

Kovacevic KD, Mayer FJ, Jilma B, Buchtele N, Obermayer G, Binder CJ, et al. Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study. Atherosclerosis. 2019;290:31–36. Available from: https://doi.org/10.1016/j.atherosclerosis.2019.09.003

Gurol G, Ciftci IH, Harman H, Karakece E, Kamanli A, Tekeoglu I. Roles of claudin-5 and von Willebrand factor in patients with rheumatoid arthritis. International Journal of Clinical and Experimental Pathology. 2015;8(2):1979-1984. Available from: https://e-century.us/files/ijcep/8/2/ijcep0004357.pdf

Ristić GG, Subota V, Lepić T, Stanisavljević D, Glišić B, Ristić AD, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis and low cardiovascular risk: the role of von Willebrand factor activity. Nurmohamed M, editor. PLOS ONE. 2015;10(8):e0130462. Available from: https://doi.org/10.1371/journal.pone.0130462

Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51(suppl 6):vi5–vi9. Available from: https://doi.org/10.1093/rheumatology/kes279

Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl. Arthritis Care & Research. 2011;63(S11):S14–S36. Available from: https://doi.org/10.1002/acr.20621

Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, et al. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. JAAOS: Global Research and Reviews. 2018;2(3):e088. Available from: https://doi.org/10.5435/JAAOSGlobal-D-17-00088

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013;34(28):2159–2219. Available from: https://doi.org/10.1093/eurheartj/eht151

Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). Cerebrovascular Diseases. 2012;34(4):290–296. Available from: https://doi.org/10.1159/000343145

Wu MD, Atkinson TM, Lindner JR. Platelets and von Willebrand factor in atherogenesis. Blood. 2017;129(11):1415–1419. Available from: https://doi.org/10.1182/blood-2016-07-692673

Atiq F, van de Wouw J, Sorop O, Heinonen I, de Maat MPM, Merkus D, et al. Endothelial dysfunction, atherosclerosis, and increase of von Willebrand factor and factor VIII: a randomized controlled trial in Swine. Thrombosis and Haemostasis. 2021;121(05):676–686. Available from: https://doi.org/10.1055/s-0040-1722185

Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF‐dependent mechanism. Journal of Thrombosis and Haemostasis. 2014;12(2):255–260. Available from: https://doi.org/10.1111/jth.12456

Fan M, Wang X, Peng X, Feng S, Zhao J, Liao L, et al. Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis. BMC Cardiovascular Disorders. 2020;20(1):72. Available from: https://doi.org/10.1186/s12872-020-01375-7

Kato Y, Iwata A, Futami M, Yamashita M, Imaizumi S, Kuwano T, et al. Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins. Medicine. 2018;97(17):e0589. Available from: https://doi.org/10.1097/MD.0000000000010589

Foster W, Lip GYH, Raza K, Carruthers D, Blann AD. An observational study of endothelial function in early arthritis. European Journal of Clinical Investigation. 2011;42(5):510–516. Available from: https://doi.org/10.1111/j.1365-2362.2011.02607.x

Veselinovic M, Jakovljevic V, Jurisic-Skevin A, Toncev S, Djuric DM. Carotid enlargement and serum levels of von Willebrand factor in rheumatoid arthritis: a follow-up study. Clinical Rheumatology. 2012;31(12):1727–1732. Available from: https://doi.org/10.1007/s10067-012-2079-0

Galiutina O, Stanislavchuk M, Bychak O, Seheda Y. POS0552 relationship between painless myocardial ischemia with level Willebrand factor and inflammatory markers in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2022;81(Suppl 1):541.1-541. Available from: https://doi.org/10.1136/annrheumdis-2022-eular.3222

Spence JD. IMT is not atherosclerosis. Atherosclerosis. 2020;312:117–118. Available from: https://doi.org/10.1016/j.atherosclerosis.2020.09.016

Fernández-Alvarez V, Linares Sánchez M, López Alvarez F, Suárez Nieto C, Mäkitie AA, Olsen KD, et al. Evaluation of intima-media thickness and arterial stiffness as early ultrasound biomarkers of carotid artery atherosclerosis. Cardiology and Therapy. 2022;11(2):231–247. Available from: https://doi.org/10.1007/s40119-022-00261-x

Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers. Blood Coagulation & Fibrinolysis. 2014;25(3):206–216. Available from: https://doi.org/10.1097/MBC.0000000000000065

Cieślicka M, Paczuski R, Gałązka M, Dmitruk K, Kujawski S, Soszyński D, et al. Impact of physical effort on von Willebrand factor's activity and concentration in blood. Journal of Physical Education and Sport. 2020;2020(02):810-817. Available from: https://efsupit.ro/images/stories/martie2020/Art%20115.pdf

Seaman CD, Ragni MV. The effect of age on von Willebrand factor and bleeding symptoms in von Willebrand disease. Thrombosis and Haemostasis. 2020;120(08):1159–1165. Available from: https://doi.org/10.1055/s-0040-1713636

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.